---
title: "Viking Therapeutics, Inc. (VKTX.US) — 公司概况"
type: "Symbol"
locale: "zh-CN"
url: "https://longbridge.com/zh-CN/quote/VKTX.US/overview.md"
symbol: "VKTX.US"
name: "Viking Therapeutics, Inc."
parent: "https://longbridge.com/zh-CN/quote/VKTX.US.md"
datetime: "2026-04-04T21:38:06.440Z"
locales:
  - [en](https://longbridge.com/en/quote/VKTX.US/overview.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/VKTX.US/overview.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/VKTX.US/overview.md)
---

> 支持的语言: [English](https://longbridge.com/en/quote/VKTX.US/overview.md) | [繁體中文](https://longbridge.com/zh-HK/quote/VKTX.US/overview.md)


# Viking Therapeutics, Inc. (VKTX.US) — 公司概况

## 基本信息

| 项目 | 详情 |
|------|--------|
| 行业 | Biotechnology |
| 交易所 | US Market |
| 地址 | 9920 Pacific Heights Boulevard, Suite 350, San Diego, California, United States |
| 官网 | [www.vikingtherapeutics.com](https://www.vikingtherapeutics.com) |

## 公司简介

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. The company develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, which is in Phase II clinical trials for metabolic disorders and anemia; VK2735, a novel dual agonist of the glucagon-like peptide 1, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.

## 核心管理层

| 名称 | 职位 |
|------|-------|
| Brian Lian | President, CEO & Director |
| Lawson MacArtney | Independent Chairman |
| Gregory S. Zante | Chief Financial Officer |
| Marianne Mancini | Chief Operating Officer |
| Michael Morneau | Vice President of Finance & Administration |
| Kenneth J. Herman | Senior Vice President of Commercial, Marketing & Sales |
| J. Matthew Singleton | Independent Director |
| Charles A. Rowland | Independent Director |
| Sarah Kathryn Rouan | Independent Director |

## 主要股东

| 名称 | 占比 | 报告日期 |
|------|-------|-------------|
| The Vanguard Group, Inc. | 8.64% | 2025-12-31 |
| BlackRock, Inc. | 5.72% | 2025-12-31 |
| FMR LLC | 5.64% | 2025-12-31 |
| State Street Global Advisors, Inc. | 3.85% | 2025-12-31 |
| Morgan Stanley | 2.47% | 2025-12-31 |
| Two Sigma Investments, LP | 2.11% | 2025-12-31 |
| Brian Lian | 1.85% | 2026-01-05 |
| Two Sigma Advisers, LP | 1.84% | 2025-12-31 |
| Geode Capital Management, LLC | 1.73% | 2025-12-31 |
| Citadel Advisors LLC | 1.50% | 2025-12-31 |


---

> **免责声明: 本文仅供参考，不构成任何投资建议。**